With CAGR 15.90, The Global Medical Simulation Market Is Forecasted To Grow By USD 9.17 Bn During 2023-2 - Benzinga
AB Stock | EUR 0.80 0.02 2.44% |
About 62% of AB Science's investor base is looking to short. The analysis of current outlook of investing in AB Science SA suggests that many traders are alarmed regarding AB Science's prospects. The current market sentiment, together with AB Science's historical and current headlines, can help investors time the market. In addition, many technical investors use AB Science SA stock news signals to limit their universe of possible portfolio assets.
AB Science |
With CAGR 15.90, The Global Medical Simulation Market Is Forecasted To Grow By USD 9.17 Bn During 2023-2 Benzinga
Read at news.google.com
AB Science Fundamental Analysis
We analyze AB Science's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AB Science using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AB Science based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
AB Science is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
AB Science SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AB Science stock to make a market-neutral strategy. Peer analysis of AB Science could also be used in its relative valuation, which is a method of valuing AB Science by comparing valuation metrics with similar companies.
Peers
AB Science Related Equities
VIRP | Virbac SA | 0.93 | ||||
GBT | Guerbet S | 0.38 | ||||
BB | Socit BIC | 0.16 | ||||
BIM | Biomerieux | 0.20 | ||||
BON | Bonduelle SCA | 0.48 |
Complementary Tools for AB Science Stock analysis
When running AB Science's price analysis, check to measure AB Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AB Science is operating at the current time. Most of AB Science's value examination focuses on studying past and present price action to predict the probability of AB Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AB Science's price. Additionally, you may evaluate how the addition of AB Science to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |